Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
- 1 April 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 22 (5) , 505-538
Abstract
We describe herein the therapeutic targets involved in Alzheimer’s disease as well as the available drugs and their synthetic routes. Bioactive compounds under development are also exploited to illustrate some recent research advances on the medicinal chemistry of Alzheimer’s disease, including structure-activity relationships for some targets. The importance of multi-target approaches, including some examples from our research projects, guides new perspectives in search of more effective drug candidates. This review comprises the period between 2001 and early 2020.Keywords
Funding Information
- São Paulo Research Foundation (2018/00187-7)
- FAPEMIG (CEXAPQ-00241-15)
- CNPq (454088/2014-0, 400271/2014-1, 310082/2016-1)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (001)
This publication has 132 references indexed in Scilit:
- Synaptic Released Zinc Promotes Tau Hyperphosphorylation by Inhibition of Protein Phosphatase 2A (PP2A)Journal of Biological Chemistry, 2012
- Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuseFrontiers in Systems Neuroscience, 2012
- 5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessmentNeuropharmacology, 2011
- A phase II trial of huperzine A in mild to moderate Alzheimer diseaseNeurology, 2011
- Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloidFrontiers in Molecular Neuroscience, 2011
- Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's DiseaseCell, 2010
- Molecular mechanisms of neurodegeneration in Alzheimer's diseaseHuman Molecular Genetics, 2010
- Drug development for Alzheimer's disease: Where are we now and where are we headed?The American Journal of Geriatric Pharmacotherapy, 2009
- Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trialNutrition & Metabolism, 2009
- The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatumBiochemical Pharmacology, 2007